Metropolis Healthcare Ltd. (METROPOLIS) AI Stock Analysis

Top Page

Metropolis Healthcare Ltd.

(NSE:METROPOLIS)

Select Model

Rating:70.2Outperform

Price Target:INR 607.00▲(11.35% Upside)

Action:reiterated

Date:08/19/26

The overall score is driven primarily by strong financial performance, including solid profitability, a healthier balance sheet, and consistent cash generation, while a high valuation multiple and subdued short‑term technical momentum prevent a higher rating.

Positive Factors

Revenue re-accelerationA stronger top-line trajectory indicates improving demand for diagnostic services and supports operating scale. Sustained volume growth across routine and specialized testing can reinforce Metropolis's market reach over the next several quarters.

Negative Factors

Profitability below prior peakEarnings have not kept pace with the expanded revenue base, indicating that cost control, pricing or service mix may be limiting operating leverage. Persistent margin variability could constrain the durability of future profit growth.

Metropolis Healthcare Ltd. (METROPOLIS) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 112.93B
Dividend Yield: 0.37%
Average Volume (3M): 33.62K
Price to Earnings (P/E): 56.1
Beta (1Y): 0.70
Revenue Growth: 21.80%
EPS Growth: 31.84%
Country: India
Employees: 4,484
Sector: General
Sector Strength: 55
Industry: Medical - Diagnostics & Research

Metropolis Healthcare Ltd. Business Overview & Revenue Model

Company Description

Metropolis Healthcare Limited functions as a prominent diagnostic service provider throughout India. The company delivers a comprehensive array of clinical laboratory testing, specialized diagnostic profiles, and associated support services. Its capa...

How the Company Makes Money

Metropolis Healthcare primarily makes money by charging fees for diagnostic testing and related laboratory services. Its key revenue streams typically include: (1) business-to-consumer (B2C) revenue from walk-in and home-collection customers who pay...

Metropolis Healthcare Ltd. Financial Statement Overview

Summary

Score reflects steadily growing revenue, consistently positive operating and free cash flow, and a strengthened, conservatively financed balance sheet, partially offset by margin compression, lower returns on equity, and some volatility in free cash flow growth.

Income Statement

76Positive

Balance Sheet

82Very Positive

Cash Flow

78Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	17.10B	16.46B	13.31B	12.08B	11.48B	12.28B
Gross Profit	9.66B	7.87B	10.28B	9.38B	8.74B	9.31B
EBITDA	4.36B	4.17B	3.04B	2.90B	2.93B	3.45B
Net Income	2.02B	1.90B	1.45B	1.28B	1.43B	2.14B
Balance Sheet
Total Assets	0	21.38B	18.67B	15.55B	15.02B	15.30B
Cash, Cash Equivalents and Short-Term Investments	2.03B	2.03B	1.18B	1.24B	1.20B	1.81B
Total Debt	0	2.32B	2.04B	1.97B	2.66B	3.79B
Total Liabilities	-15.25B	6.13B	5.33B	4.56B	5.11B	6.42B
Stockholders Equity	15.25B	15.13B	13.31B	10.96B	9.88B	8.86B
Cash Flow
Free Cash Flow	0	2.99B	2.19B	2.00B	1.94B	2.23B
Operating Cash Flow	0	3.50B	2.63B	2.64B	2.47B	2.53B
Investing Cash Flow	0	-2.18B	-2.01B	-894.12M	467.94M	-7.38B
Financing Cash Flow	0	-1.20B	-866.34M	-1.81B	-2.92B	1.63B

Metropolis Healthcare Ltd. Technical Analysis

Technical Analysis SentimentPositive

Last Price545.15

Price Trends

50DMA561.35Negative

100DMA559.54Negative

200DMA520.87Positive

Market Momentum

MACD-4.88Negative

RSI49.44Neutral

STOCH75.08Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:METROPOLIS, the sentiment is Positive. The current price of 545.15 is above the 20-day moving average (MA) of 536.35, below the 50-day MA of 561.35, and above the 200-day MA of 520.87, indicating a neutral trend. The MACD of -4.88 indicates Negative momentum. The RSI at 49.44 is Neutral, neither overbought nor oversold. The STOCH value of 75.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:METROPOLIS.

Metropolis Healthcare Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:METROPOLIS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:LALPATHLAB	74Outperform	INR 319.97B	58.77	―	0.84%	14.29%	5.55%
IN:VIJAYA	71Outperform	INR 149.06B	79.30	―	0.14%	20.18%	24.71%
IN:METROPOLIS	70Outperform	INR 113.09B	56.06	―	0.37%	21.80%	31.84%
IN:VIMTALABS	69Neutral	INR 21.67B	27.15	―	0.41%	14.22%	7.17%
IN:THYROCARE	65Neutral	INR 72.74B	50.42	―	2.04%	21.99%	12.77%
IN:KRSNAA	61Neutral	INR 16.35B	16.77	―	0.40%	10.19%	20.99%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:METROPOLIS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:METROPOLIS	Metropolis Healthcare Ltd.	545.15	46.06	9.23%
IN:KRSNAA	Krsnaa Diagnostics Limited	504.10	-281.30	-35.82%
IN:LALPATHLAB	Dr. Lal PathLabs Limited	1906.30	296.36	18.41%
IN:THYROCARE	Thyrocare Technologies Ltd	457.00	2.20	0.48%
IN:VIJAYA	Vijaya Diagnostic Centre Ltd.	1447.25	429.81	42.24%
IN:VIMTALABS	Vimta Labs Limited	484.85	-194.79	-28.66%

Metropolis Healthcare Ltd. Corporate Events

Metropolis Healthcare Q1FY27 Update Shows Double-Digit Growth and Margin Gains

Jul 5, 2026

Metropolis Healthcare reported about 16% year-on-year revenue growth in the June 2026 quarter, driven primarily by higher patient volumes and improved realization from a favorable product mix. The TruHealth wellness and specialty businesses emerged a...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026

Metropolis Healthcare Ltd. AI Stock Analysis

Top Page